Munich (DE), October 5th, 2023 Hypertrust Patient Data Care GmbH (HPDC) today announced its transition into a subsidiary of Elixum GmbH an innovative provider of next-generation supply chain planning . As part of these changes, HPDC has been renamed Hypertrust GmbH. The changes will have no impact on Hypertrust customers and partners.
This strategic integration reaffirms both companies’ dedication to enabling orchestration of supply chains of ATMP (Advanced Therapy Medicinal Products) at a new level. “We are excited to embark on this new chapter as part of an innovative company like Elixum GmbH. This step paves the way for many synergies to the benefit of our customers,” said Andreas Göbel, Managing Director of Hypertrust. With this transition he will take the new role of Chief Innovation Officer at Elixum GmbH while still being responsible for the Hypertrust ATMP orchestration solutions.
Uninterrupted Service: Hypertrust’s Transition to Hypertrust GmbH has no Impact on Customers and Partners
The changes will have no impact on existing solutions and services, or partner relationships. Customer contracts, Hypertrust contacts and support services will remain unchanged. All customers can continue to rely on the expertise of the Hypertrust team with Hypertrust X-Chain as the leading orchestration solution for ATMP.
Strategic Integration and Name Change: Hypertrust Becomes a Subsidiary of Elixum GmbH
The name change from Hypertrust Patient Data Care to Hypertrust is intended to emphasize the company’s focus on ATMP supply chains. The supply chain management solution for ATMP Hypertrust X-Chain will continue to benefit from Elixum’s planning portfolio which was already an integral part of the full feature set.
The next chances to meet the the Hypertrust Team and experience the enhanced benefits of the Hypertrust X-chain solution will be in Brussels at the BSMA from 19 to 20 October, 2023.
